Recent briefings through mid-June 2026 did not identify discrete Pfizer-specific corporate news events in the 30 days preceding this report's generation date of 2026-06-25. The broader macro environment over this period was marked by heightened geopolitical uncertainty, including reported US-Iran tensions following the interception of Iranian missiles aimed at American forces in Kuwait, which introduced volatility across equity and energy markets [Brief - 2026-06-17]. No Pfizer-specific product announcements, regulatory decisions, or executive changes were captured in the available briefing data for this period.
Pfizer's trailing twelve-month revenue stood at $63.32 billion as of the most recent filing, representing year-over-year growth of 5.37%. Net income for the same period was $7.49 billion, with a net margin of 11.83% and an operating margin of 35.40%. EPS declined 9.62% year-over-year. The company held $1.70 billion in cash against total debt of $64.46 billion. The reported price-to-earnings ratio was 18.35 [SEC 10-Q - PFE - 2026-03-29].
Insider activity in June 2026 recorded a single transaction with a net selling direction, totalling a net disposal value of approximately $51,400 [SEC Form 4 - PFE - 2026-06]. On the institutional side, Citadel reduced its PFE position by 17%, while AQR Capital added 21% to its position and Millennium added 9.9% to its position, reflecting divergent activity among major quantitative and multi-strategy funds [SEC 13F - Citadel - Q1 2026] [SEC 13F - AQR Capital - Q1 2026] [SEC 13F - Millennium - Q1 2026].
The US 10-year Treasury yield stood at 4.50% and the 2-year yield at 4.16%, reflecting a normal yield curve configuration at the time of this report [FRED DGS10] [FRED DGS2]. This rate environment represents the prevailing cost-of-capital backdrop against which Pfizer's debt load of $64.46 billion is carried.
This report was generated in response to material institutional position changes in Pfizer Inc. as reflected in the most recent 13F filings, with Citadel, AQR Capital, and Millennium each recording notable adjustments to their reported PFE holdings in the latest disclosure cycle.